Clinical trials: Type 1 and 2 Diabetes
Diabetic Ketoacidosis, Type 1 Diabetes
Early Basal Insulin Administration in Adult Diabetic Ketoacidosis Management
Early Basal Insulin Administration in Adult Diabetic Ketoacidosis Management
- Conditions
- Diabetic Ketoacidosis, Type 1 Diabetes, Type 2 Diabetes
- Trial name
- NCT04567225
- Testing
- Early Glargine, Late Glargine, IV insulin infusion
- Where
- United States
- Volunteers
- 39 people
- Sponsor
- The Cleveland Clinic
Type 2 Diabetes Mellitus
Pharmacokinetics Study of Dipeptidyl Peptidase 4 Inhibitor to Control Type 2 Diabetes Mellitus
The purpose of this study is to confirm the mechanism of reduced response to DPP-4 inhibitor in some patients with type 2 diabetes and evaluate appropriate patients to treat with DPP-4 inhibitor
- Trial name
- NCT01449747
- Testing
- Sitagliptin
- Where
- 2 sites in South Korea
- Volunteers
- 24 people
- Sponsor
- The Catholic University of Korea
Type 2 Diabetes Mellitus (T2DM)
Multiple Dose Study Of PF-05231023 In Obese Adult Subjects
This is a trial in obese subjects to study the safety, tolerability, pharmacokinetics and pharmacodynamics of multiple doses of PF-05231023.
- Trial name
- NCT01923389
- Testing
- 100 mg PF-05231023
- Where
- 2 sites in United States
- Volunteers
- 4 people
- Sponsor
- Pfizer
Diabetes Mellitus, Type 1
Omnipod® 5 With Libre 2 vs. MDI for Type 1 Diabetes in Children and Adults
This study is a randomized, controlled trial to evaluate the efficacy and safety of the Omnipod® 5 System with the FreeStyle Libre 2 continuous glucose monitor compared to Multiple Daily Injections (MDI) along with the FreeStyle…
- Trial name
- RADIANT (NCT05923827)
- Testing
- Omnipod 5 System
- Where
- 19 sites in Belgium, France and 1 more
- Volunteers
- 189 people
- Sponsor
- Insulet Corporation
Type 1 Diabetes Mellitus
Effect of a Fixed Pramlintide: Insulin Dose Ratio on Postprandial Glucose in Type 1 Diabetes Mellitus
This study is designed to investigate the clinical efficacy and safety of pramlintide co-administered as a fixed-dose ratio with basal-bolus SC insulin, delivered simultaneously via 2 separate pumps, in subjects with type 1…
- Trial name
- NCT02500979
- Testing
- Pramlintide acetate, Lispro insulin U-100, Regular insulin U-100
- Where
- 3 sites in United States
- Volunteers
- 34 people
- Sponsor
- AstraZeneca
Type 2 Diabetes Mellitus
Study to Evaluate Effects of Probenecid, Rifampin and Verapamil on Bexagliflozin in Healthy Subjects
The purpose of this study is to examine the drug-drug interaction when given the study drug, bexagliflozin, with three commonly prescribed medications, probenecid, verapamil or rifampin.
- Trial name
- NCT03296800
- Testing
- Bexagliflozin, Probenecid, Rifampin
- Where
- United States
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Theracos
Type 2 Diabetes Mellitus, Coronary Artery Disease
Effects of Agonists of Glucagon Like Peptide - 1 Receptors (GLP-1R) on Arterial Stiffness, Endothelial Glycocalyx and Coronary Flow Reserve in Patients With Coronary Artery Disease and Patients With Diabetes Mellitus
Arterial stiffness is associated with increased risk for cardiovascular disease. Moreover, the integrity of endothelial glycocalyx plays a vital role in vascular permeability, inflammation and elasticity.
- Trial name
- NCT03010683
- Testing
- Liraglutide, Metformin
- Where
- Greece
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- University of Athens
Overweight, Obese
A Study of CT-868 in Type 1 Diabetes Mellitus
This study will evaluate the changes in glycemic control in overweight and obese adults with Type 1 Diabetes Mellitus after receiving CT-868 for 16 weeks. The effectiveness and safety of CT-868 will be compared to placebo.
- Conditions
- Overweight, Obese, Type 1 Diabetes Mellitus
- Trial name
- NCT06062069
- Testing
- CT-868, CT-868 Pen Injector
- Where
- 22 sites in United States
- Volunteers
- 111 people
- Sponsor
- Carmot Therapeutics, Inc.
Diabetes Mellitus, Diabetes Mellitus, Type 1
PRECISION Study: Multi-center Study of Performance of a Novel Implanted CGM System Using a Next Generation Transmitter and Algorithm
The purpose of this multi-center, prospective clinical study is to evaluate the performance of a novel, implanted Senseonics continuous glucose monitoring system (Senseonics CGM System) compared to Yellow Springs Instrument (YSI)…
- Conditions
- Diabetes Mellitus, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2
- Trial name
- PRECISION (NCT03251079)
- Testing
- Continuous glucose monitoring system
- Where
- 3 sites in United States
- Volunteers
- 36 people
- Sponsor
- Senseonics, Inc.
Pancreatic Islet Transplantation in Type 1 Diabetes Mellitus
Reparixin in Pancreatic Islet Transplantation
Inhibition of CXCL8 activity might represent a relevant therapeutic target to prevent injury occurring after pancreatic islet transplantation. Reparixin is a novel and specific inhibitor of CXCL8.
- Trial name
- NCT01220856
- Testing
- Reparixin
- Where
- 2 sites in Germany, Italy
- Volunteers
- 9 people
- Sponsor
- Dompé Farmaceutici S.p.A
Diabetes, Diabetes Mellitus, Type 2
Safety and Efficacy of Oral Semaglutide Versus Dulaglutide Both in Combination With One OAD (Oral Antidiabetic Drug) in Japanese Subjects With Type 2 Diabetes
This trial is conducted in Asia. The aim of this trial is to investigate Safety and efficacy of oral semaglutide versus dulaglutide both in combination with one OAD (oral antidiabetic drug) in Japanese subjects with type 2…
- Trial name
- PIONEER 10 (NCT03015220)
- Testing
- Semaglutide, Dulaglutide
- Where
- 34 sites in Japan
- Volunteers
- 458 people
- Sponsor
- Novo Nordisk A/S
Diabetes, Diabetes Mellitus, Type 2
Comparison of NN5401 With Biphasic Insulin Aspart 30 in Type 2 Diabetes
This trial is conducted in Asia, Europe and Oceania. The aim of this clinical trial is to compare NN5401 (insulin degludec/insulin aspart) with biphasic insulin aspart 30 in subjects with type 2 diabetes.
- Trial name
- BOOST™ (NCT01009580)
- Testing
- insulin degludec/insulin aspart, biphasic insulin aspart 30
- Where
- 53 sites in Australia, Denmark and 8 more
- Volunteers
- 447 people
- Sponsor
- Novo Nordisk A/S
Gestational Diabetes Mellitus, Type 2 Diabetes Mellitus
Combined Liraglutide and Metformin Therapy in Women With Previous Gestational Diabetes Mellitus (GDM)
A diagnosis of gestational diabetes mellitus (GDM)has significant implications for the future health of the mother. GDM is often the culmination of years of unrecognized and unmodified diabetes risk factors that lead to overt and…
- Conditions
- Gestational Diabetes Mellitus, Type 2 Diabetes Mellitus, Metabolic Syndrome, Impaired Glucose Tolerance
- Trial name
- NCT01234649
- Testing
- Metformin XR plus liraglutide
- Where
- United States
- Volunteers
- 153 people, healthy volunteers welcome
- Sponsor
- Woman's
Type 2 Diabetes Mellitus
TAK-648 Multiple-Rising Dose Study in Healthy Japanese Participants and Non-Japanese Participants With Type 2 Diabetes Mellitus
This is a phase 1, randomized, double-blind, placebo-controlled, 2-center, multiple-dose study in healthy participants and participants with type 2 diabetes mellitus (T2DM).
- Trial name
- NCT02430870
- Testing
- TAK-648
- Where
- 2 sites in United States
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Takeda
Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2
Empagliflozin and ACEi- Effects on Hyperfiltration: BETWEEN Study
This is a randomized, double-blind, double-dummy, placebo-controlled, cross over design trial with empagliflozin compared to placebo that is added to open-label ramipril.
- Conditions
- Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2, Obesity
- Trial name
- NCT02632747
- Testing
- Empagliflozin, ramipril
- Where
- Canada
- Volunteers
- 31 people
- Sponsor
- Boehringer Ingelheim
Diabetes Mellitus, Type 2
Insulin Glargine "All to Target" Trial
The primary objectives were: To demonstrate the superiority of Lantus plus stepwise addition of mealtime Apidra® (Lantus/Apidra-3) versus twice-daily Premixed insulin based on the proportion of patients achieving target glycemic…
- Trial name
- NCT00384085
- Testing
- Insulin Glulisine, Insulin Glargine, Premixed Insulin
- Where
- United States
- Volunteers
- 588 people
- Sponsor
- Sanofi
Type 2 Diabetes Mellitus
A Study of Tirzepatide (LY3298176) Compared With Dulaglutide on Major Cardiovascular Events in Participants With Type 2 Diabetes
The purpose of the trial is to assess the efficacy and safety of tirzepatide to dulaglutide in participants with type 2 diabetes and increased cardiovascular risk.
- Trial name
- SURPASS-CVOT (NCT04255433)
- Testing
- Tirzepatide, Dulaglutide
- Where
- 635 sites in United States, Argentina and 29 more
- Volunteers
- 13,299 people
- Sponsor
- Eli Lilly and Company
Diabetes Mellitus, Type 1
Comparison of Two Basal Insulin Therapies for Patients With Type 1 Diabetes
The purpose of this study is to examine the efficacy and safety of insulin lispro protamine suspension (ILPS) as compared to insulin detemir as basal insulin combined with mealtime insulin therapy in patients with type 1…
- Trial name
- IOOZ (NCT00487240)
- Testing
- Insulin Lispro Protamine Suspension, Insulin Levemir
- Where
- 28 sites in United States, Argentina and 7 more
- Volunteers
- 387 people
- Sponsor
- Eli Lilly and Company
Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2
Research Study to Compare a New Medicine "Fast-acting Insulin Aspart" to Another Medicine "Insulin Aspart" in Chinese People With Diabetes
Fast-acting insulin aspart (faster aspart) will be tested to see how well it works and if it is safe. The study compares 2 medicines for type 1 and type 2 diabetes - faster aspart (a new medicine) and insulin aspart (a medicine…
- Trial name
- NCT04588259
- Testing
- Faster aspart, Insulin aspart, Insulin degludec
- Where
- 40 sites in China, Hong Kong
- Volunteers
- 331 people
- Sponsor
- Novo Nordisk A/S
Diabetes, Diabetes Mellitus, Type 2
Research Study Comparing a New Medicine Semaglutide to Liraglutide in People With Type 2 Diabetes
This study is conducted in Europe. The aim of the study is to compare the effect of semaglutide subcutaneous (s.c., under the skin) 1.0 mg once-weekly to liraglutide s.c.1.2 mg once-daily on blood sugar levels after 30 weeks of…
- Trial name
- SUSTAIN 10 (NCT03191396)
- Testing
- Semaglutide, Liraglutide
- Where
- 92 sites in Bulgaria, Czechia and 10 more
- Volunteers
- 577 people
- Sponsor
- Novo Nordisk A/S